Everything below concerns melanogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
On February 11, 1869, Jose Rosell was imprisoned by the Spanish government with several others on the charge of being a Freemason. On March 21, they were deported to the brutal Penal colony at Fernando Poo, Spanish Guinea. Some time later, Rosell was taken to the notorious prison of San Juan de Ulúa at Vera Cruz. There is an implication that Rosell was tortured, and after this Lodge No. 12 was persecuted greatly by the Spanish. After this, all Cuban Lodges were ordered to suspend their activities. Most Lodges stopped meeting at their temples altogether, and started holding meetings at their own houses. Vicente Antonio de Castro died on May 12, 1869.
A seminal work of traditional Chinese medicine was the Huangdi neijing (Yellow Emperor's Inner Canon) compiled between the 3rd and 2nd centuries BC (i.e. originating in the Warring States period), which viewed the human body, its organs and tissues through the lens of the metaphysical five phases and yin and yang, and stated a belief in two circulatory channels of qi vital energy. In surgery, Han dynasty era Chinese texts offered practical advice for certain procedures such as clinical lancing of abscesses. The first known physician in China to describe the use anesthesia for patients undergoing surgery was the Eastern Han physician Hua Tuo (d. 208 AD), who utilized his knowledge of Chinese herbology based in the Huangdi neijing to create an ointment that healed surgical wounds within a month. One of his surgical procedures was the removal of a dead fetus from the womb of a woman whom he diagnosed and cured of her ailments.
The dairy industry market size in Haryana is predicted to grow at 15% CAGR from 2021 to 2026, major players being Vita, Amul, Mother Dairy, Kwality, etc. In 2025, Amul's Sabar Dairy Plant at IMT Rohtak was expanded making it India's largest processing plant for curd, buttermilk, and yoghurt catering for the Haryana, Delhi-NCR, and northern India region. In 2025, Haryana was India's third largest producer of milk (122.2 lakh tonnes per year) with highest per capita milk availability in India (1,105 grams per day). Rich in zinc, calcium, proteins, magnesium, and vitamin D and B12, milk can be turned into various products such as liquid milk, ghee, curd, paneer, ice-cream, table butter, skimmed milk powder, frozen/flavoured yoghurt, fresh cream, lassi, butter milk, cheese, flavoured milk, UHT milk, dairy whitener, sweet condensed milk, infant food, and malt-based beverages.
Sources: en.wikipedia.org
In her 2008 book The How of Happiness, Sonja Lyubomirsky similarly argued people's happiness varies around a genetic set point. Diener warns, however, that it is nonsensical to claim that "happiness is influenced 30–50% by genetics". Diener explains that the recipe for happiness for an individual always requires genetics, environment, and behaviour too, so it is nonsensical to claim that an individual's happiness is due to only one ingredient. Only differences in happiness can be attributed to differences in factors. In other words, Lyubomirsky's research does not discuss happiness in one individual; it discusses differences in happiness between two or more people. Specifically, Lyubomirsky suggests that 30–40% of the difference in happiness levels is due to genetics (i.e. heritable). In other words, still, Diener says it makes no sense to say one person's happiness is "due 50% to genetics", but it does make sense to say one person's difference in happiness is 50% due to differences in their genetics (and the rest is due to behaviour and environment). Findings from twin studies support the findings just mentioned. Twins reared apart had nearly the same levels of happiness thereby suggesting the environment is not entirely responsible for differences in people's happiness. Importantly, an individual's baseline happiness is not entirely determined by genetics, and not even by early life influences on one's genetics.
This inhibition can lead to a depletion of dopamine and norepinepherine in the brain due to the lack of the precursor L-DOPA (L-3,4-dyhydroxyphenylalanine) which is synthesized by tyrosine hydroxylase. This drug is rarely used and can cause depression, but it is useful in treating pheochromocytoma and also resistant hypertension. Older examples of inhibitors mentioned in the literature include oudenone and aquayamycin.
March 22 – Air Canada Express Flight 8646: Two pilots are killed and more than 40 passengers injured when a Bombardier CRJ700 collides with a firetruck while attempting to cross a runway at LaGuardia Airport, New York. March 23 Trump announces a postponement of U.S. strikes against Iranian power plants after what he calls "productive" negotiations. However, Iran's foreign ministry denies that such talks have taken place. 2026 United States federal government shutdowns: ICE agents are sent to airports to assist TSA agents who are without pay. A jury in California finds that Bill Cosby is liable for raping a woman by the name of Donna Motsinger in 1972 and awards $19 million in damages to her. The Trump administration announces that it will pay $1 billion to French company TotalEnergies to cancel planned offshore wind farms in the Atlantic and instead pursue fossil fuel projects. March 24 The U.S. Senate confirms Markwayne Mullin as the 9th DHS Secretary in a 54–45 vote. Secretary Mullin is the first member of the Cherokee Nation to serve in the U.S. Cabinet. Former Kentucky governor Matt Bevin is held in contempt of court and is sentenced to either 60 days in prison or a $500 fine. Democrat Emily Gregory wins a special election to represent the 87th House district of Florida which contains Mar-a-Lago. March 25 Expansion of the NBA: The National Basketball Association Board of Governors approve a vote to explore expansion bids in Las Vegas and Seattle. A jury in California finds that Meta and YouTube are liable for social media addiction.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.